|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.34 USD | -1.61% |
|
-3.67% | -2.17% |
| 08:14am | Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar | DP |
| 12-08 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| Capitalization | 246B 211B 198B 184B 340B 22,063B 369B 2,295B 892B 10,457B 921B 902B 38,529B | P/E ratio 2025 * |
12.8x | P/E ratio 2026 * | 13.2x |
|---|---|---|---|---|---|
| Enterprise value | 271B 233B 218B 203B 375B 24,339B 407B 2,532B 984B 11,536B 1,017B 995B 42,505B | EV / Sales 2025 * |
4.18x | EV / Sales 2026 * | 3.82x |
| Free-Float |
70.67% | Yield 2025 * |
3.27% | Yield 2026 * | 3.42% |
Last Transcript: Merck & Co., Inc.
| 1 day | -1.62% | ||
| 1 week | -3.67% | ||
| Current month | -7.16% | ||
| 1 month | +12.18% | ||
| 3 months | +15.02% | ||
| 6 months | +22.68% | ||
| Current year | -2.17% |
| 1 week | 96.06 |  | 103.09 |
| 1 month | 85.8 | | 105.84 |
| Current year | 73.31 | | 105.84 |
| 1 year | 73.31 | | 105.84 |
| 3 years | 73.31 | | 134.63 |
| 5 years | 70.89 | | 134.63 |
| 10 years | 47.97 | | 134.63 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 58 | 2021-06-30 |
| Director of Finance/CFO | 56 | 2021-03-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 56 | 2020-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 65 | 2007-11-26 |
Patricia Russo
BRD | Director/Board Member | 72 | 1995-08-31 |
Robert Davis
CHM | Chairman | 58 | 2022-11-30 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.34% | 303 M€ | -22.89% | - |
| 5.61% | 26 M€ | +11.55% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.61% | -3.67% | -6.23% | -10.54% | 246B | |
| -1.08% | -5.31% | +23.26% | +174.39% | 893B | |
| -0.37% | -2.06% | +34.49% | +14.48% | 486B | |
| +0.67% | +0.06% | +27.15% | +37.69% | 394B | |
| -0.76% | +0.64% | +22.59% | +3.51% | 336B | |
| +0.10% | -1.51% | +27.00% | +19.71% | 280B | |
| +0.17% | +0.58% | +19.51% | +24.96% | 253B | |
| +0.07% | -2.56% | -61.75% | -35.08% | 207B | |
| -1.32% | -6.24% | +14.27% | +13.86% | 173B | |
| -0.96% | -3.20% | +32.40% | +36.35% | 150B | |
| Average | -0.47% | -2.03% | +13.27% | +27.93% | 341.87B | |
| Weighted average by Cap. | -0.49% | -2.41% | +17.96% | +55.20% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 64.76B 55.64B 52.2B 48.64B 89.58B 5,819B 97.35B 605B 235B 2,758B 243B 238B 10,162B | 68.2B 58.6B 54.98B 51.23B 94.34B 6,128B 103B 638B 248B 2,905B 256B 251B 10,702B |
| Net income | 19.47B 16.73B 15.69B 14.62B 26.93B 1,749B 29.27B 182B 70.74B 829B 73.06B 71.51B 3,055B | 18.39B 15.8B 14.83B 13.82B 25.44B 1,653B 27.65B 172B 66.83B 783B 69.02B 67.56B 2,886B |
| Net Debt | 25.34B 21.77B 20.43B 19.03B 35.05B 2,277B 38.09B 237B 92.06B 1,079B 95.09B 93.07B 3,976B | 14.67B 12.61B 11.83B 11.02B 20.3B 1,319B 22.06B 137B 53.31B 625B 55.07B 53.9B 2,303B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-09 | 97.31 $ | -1.64% | 9,969,343 |
| 25-12-08 | 98.93 $ | -0.79% | 12,902,587 |
| 25-12-05 | 99.72 $ | -1.16% | 16,430,388 |
| 25-12-04 | 100.89 $ | -1.35% | 12,770,712 |
| 25-12-03 | 102.27 $ | +1.23% | 12,541,641 |
Delayed Quote Nyse, December 09, 2025 at 03:12 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition